Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 87 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Results available

Flexible-Dose Trial in Early Parkinson's Disease (PD)

NCT04223193
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Fresno, California • Boca Raton, Florida • Maitland, Florida + 14 more
Conditions
Parkinson's Disease
Interventions
Coenzyme Q10
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Rochester, New York
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Conditions
Parkinson's Disease
Interventions
minocycline, creatine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, New York
Terminated No phase listed Observational Accepts healthy volunteers

Early Parkinson's Disease (PD) Cross-Sectional

NCT00817453
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson's Disease
Interventions
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
Completed Phase 2 Interventional Results available

Pioglitazone in Early Parkinson's Disease

NCT01280123
Conditions
Parkinson's Disease
Interventions
Pioglitazone, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Conditions
Prodromal Parkinsons Disease
Interventions
[18F] AV-133 PET Imaging
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Conditions
Parkinson's Disease
Interventions
TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
301 participants
Timeline
2002 – 2003
U.S. locations
11
States / cities
Phoenix, Arizona • Berkley, California • Fountain Valley, California + 8 more
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Conditions
Parkinson Disease
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
31 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 32 more
Conditions
Parkinson's Disease
Interventions
RO7046015, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more
Conditions
Alzheimer Disease, Parkinson Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more
Completed Phase 2 Interventional Results available

Safety of Urate Elevation in Parkinson's Disease

NCT00833690
Conditions
Parkinson Disease
Interventions
Placebo, inosine
Drug
Lead sponsor
The Parkinson Study Group
Network
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Completed Phase 2 Interventional Results available

Early Parkinson's Disease Monotherapy With CVN424

NCT06006247
Conditions
Parkinson's Disease
Interventions
CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance Beta, Inc.
Industry
Eligibility
30 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 21 more
Conditions
Parkinson's Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
30 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
58
States / cities
Phoenix, Arizona • Sun City, Arizona • Fountain Valley, California + 51 more
Conditions
Parkinson Disease
Interventions
CoQ10, GPI 1485
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, New York
Conditions
Parkinson Disease
Interventions
Vibrotactile coordinated reset
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stanford, California
Conditions
Parkinson's Disease
Interventions
ROTIGOTINE
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Long Beach, California • Hallandale, Florida • Atlanta, Georgia
Completed Phase 3 Interventional Results available

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842
Conditions
Parkinson Disease
Interventions
Isradipine, Placebo (for Isradipine)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more